Product development

Milestones reached
High antitumor activity is shown on preclinical models of lung cancer and renal-cell carcinoma. (Altogen Labs, USA)
Prominent inhibition of angiogenesis is shown on Matrigel graft implants in mice.
5th level of toxicity (almost non-toxic) according to Hodge and Sterner scale in single-dose toxicity studies in mice. 
Humanization is completed. (PX therapeutics)
Stable cell line, medium scale production protocol and analytical methods are developed . (Goodwin Biotechnologies Inc.)
Formulation development is ongoing.
 
Further plans:
The company OncoMax completed a pre-clinical program. Currently the company is conducting studies for optimization the productivity of antibody and scale of production.